Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel
17 Enero 2019 - 06:27PM
Noticias Dow Jones
By Josh Beckerman
A diabetes drug being developed by Sanofi (SNY) and Lexicon
Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food
and Drug Administration advisory panel.
Before the 8-8 vote, Lexicon shares had been halted all day.
The FDA isn't required to follow the advice of such advisory
panels, but it generally does so. An FDA decision is expected by
March 22.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 17, 2019 19:12 ET (00:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024